Atugen Team Publishes Early Data Showing RNAi Could Have Potential for Pro- or Anti-Angiogenesis | GenomeWeb

Scientists from SR Pharma subsidiary Atugen have shown that systemically delivered siRNAs formulated with the company's liposomal technology can trigger an RNA inference effect in the vasculature of mice, although with varied levels of efficacy.

In a separate study, the researchers showed that the company's formulated siRNAs could be used to inhibit tumor growth and metastases in xenograft mouse models, apparently through angiogenesis, but cautioned that their findings were still preliminary.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.